iConsensus,Integrated control and sensing platform for biopharmaceutical cultivation process high-throughput development and production
iConsensus is funded through the Innovative Medicines Initiative 2 (IMI2) Joint Undertaking and is listed under grant agreement No. 777397. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA), Sanofi, Bayer, GSK, Pfizer, Rentschler, Synthon and UCB. IMI2 supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.
iConsensus is about the development of innovative analytical tools and control systems to ascertain robust, reproducible cell culture processes that result in the right product quality and suitable product yields, critical to the consistent manufacturing of biopharmaceuticals, and to bring safe and effective therapies to patients.
The goals of iConsensus are to provide innovative analytical, hardware, software and high-throughput (HTP) solutions for the development, monitoring and control of mammalian cell cultivation process producing biopharmaceuticals. iConsensus will develop an analytical platform with on-line/at-line sensors and detection methods measuring multiple factors in the cell culture and the produced drug protein, e.g. monoclonal antibody (MAb). Under advanced data management, the analytical platform will be integrated in new micro-bioreactors for HTP screening on one hand and in classical stirred tank vessel bioreactors on the other hand. Based on the analytical information, feedback control will be applied. Implementation in GMP production of the sensing and control tools will be a major goal.
Project Coordinator: Veronique Chotteau
Active from CETEG: Meeri Mäkinen (Post-doc), Atefeh Shokri (Researcher)